Furthermore, single-agent doxercalciferol was studied in CRPC (12.5 mg per os) among 26 patients: it did not reach statistical significance, with no substantial decrease in PSA; paricalcitol was evaluated on a 3-times-per-week schedule and, while it was very well tolerated and safe to use, it did not demonstrate a serum PSA reduction [ 147 , 148 ].
← all excerpts
The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies.
1
—
—